Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06344715
Status:
RECRUITING
Last Update Posted:
2024-04-03
First Post:
2024-03-19
Brief Title:
Phase 1 Study Evaluating Safety and Tolerability of SL-T10 GX-I7 and Pembrolizumab Triple Combination in mCRPC
Sponsor:
SL VAXiGEN
Organization:
SL VAXiGEN
Study Overview
Official Title:
A Phase 1 Multi-center Open-label Dose-escalating Study to Evaluate the Safety and Tolerability of Triple Combination Regimen of SL-T10 GX-I7 and Pembrolizumab in Patients With Metastatic Castration-resistant Prostate Cancer mCRPC
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of SL-T10 and GX-I7 or SL-T10 GX-I7 and pembrolizumab in patients with metastatic castration-resistant prostate cancer mCRPC
Detailed Description:
The purpose of this study is to evaluate the safety tolerability and preliminary efficacy of SL-T10 GX-I7 and pembrolizumab in combination in patients with metastatic castration-resistant prostate cancer mCRPC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None